戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  host-microbiome regulatory interface during pouchitis.
2  provide long-term benefit for patients with pouchitis.
3 the microbiome and host transcriptome during pouchitis.
4 ission in patients with antibiotic-dependent pouchitis.
5 s open-labeled trial of antibiotic-dependent pouchitis.
6 tiating between irritable pouch syndrome and pouchitis.
7 on complication of this surgery, however, is pouchitis.
8 nt of antibiotic dependence in patients with pouchitis.
9 tis and chronic pouchitis and delay onset of pouchitis.
10 ther CD of the colon, ulcerative colitis, or pouchitis.
11 f quiescent ulcerative colitis and relapsing pouchitis.
12  of Crohn's disease, ulcerative colitis, and pouchitis.
13      Symptoms alone do not reliably diagnose pouchitis.
14 t the intestinal microbiome of patients with pouchitis.
15 id not meet the PDAI diagnostic criteria for pouchitis.
16 nd clinical outcome in patients with chronic pouchitis.
17  those patients, one fifth will have chronic pouchitis.
18  clinical implications for the management of pouchitis.
19 g probiotics for the prevention of recurrent pouchitis.
20 gests using antibiotics for the treatment of pouchitis.
21  poor function (18 [30%]: 2 early, 16 late), pouchitis (7 [11%]: 2 early, 5 late) and miscellaneous (
22  2 carriage rate compared with those without pouchitis (72% vs. 45%) and Kaplan-Meier survival analys
23 to be at greater risk for the development of pouchitis after IAPT.
24 dication for colectomy and the occurrence of pouchitis after ileal pouch-anal anastomosis formation.
25 1 receptor antagonist gene allele 2 predicts pouchitis after ileal pouch-anal anastomosis in ulcerati
26 s (UC), aggressive Crohn's disease (CD), and pouchitis after restorative proctocolectomy.
27 ducing remission in patients who had chronic pouchitis after undergoing IPAA for ulcerative colitis.
28 s recurrent-acute pouchitis (n = 6), chronic pouchitis and Crohn's-like disease of the pouch (n = 27)
29 ion considerations for optimal management of pouchitis and Crohn's-like disease of the pouch and iden
30 se relapse of ulcerative colitis and chronic pouchitis and delay onset of pouchitis.
31 lyzed tissues from patients with and without pouchitis and from patients with ulcerative colitis usin
32 own the benefits of a range of probiotics in pouchitis and in ulcerative colitis, although current ev
33 o support practitioners in the management of pouchitis and inflammatory pouch disorders.
34  approach to the management of patients with pouchitis and other inflammatory conditions of the pouch
35 ccus salivarius prevent relapse of recurrent pouchitis and perhaps decrease the initial onset of pouc
36   Features of intestinal inflammation during pouchitis and ulcerative colitis are similar, which may
37 al anastomosis (IPAA) will subsequently have pouchitis, and among those patients, one fifth will have
38  bowel syndrome, inflammatory bowel disease, pouchitis, and colonic diverticular disease.
39 potentially prevent and treat Crohn disease, pouchitis, and possibly ulcerative colitis, but optimal
40 y, risk factors, diagnosis and management of pouchitis, and pouch surveillance for neoplasia in patie
41 tients with UC with normal pouch/ileum, CDP, pouchitis, and those with familial adenomatous polyposis
42 tion; inflammatory bowel diseases, including pouchitis; and irritable bowel syndrome.
43     Crohn's disease, ulcerative colitis, and pouchitis are caused by overly aggressive immune respons
44     Crohn's disease, ulcerative colitis, and pouchitis are the result of continuous microbial antigen
45 2, with higher scores indicating more severe pouchitis) at week 14.
46 8, with higher scores indicating more severe pouchitis) at weeks 14 and 34.
47 ators in CDP were similar to those in CD and pouchitis, but not UC.
48 ch revision and later complications, such as pouchitis, can mandate pouch excision.
49 s had a significantly increased incidence of pouchitis compared with noncarriers (log-rank test, 6.5)
50 ndations for the prevention and treatment of pouchitis, Crohn's-like disease of the pouch, and cuffit
51 be due to inflammatory conditions, including pouchitis, cuffitis, or Crohn's disease or noninflammato
52 ith irritable pouch syndrome from those with pouchitis, cuffitis, or Crohn's disease with a sensitivi
53                  Eight patients with chronic pouchitis (current PDAI >/=7) were treated with FMT via
54  25% of patients with symptoms suggestive of pouchitis did not meet the PDAI diagnostic criteria for
55           The primary end point was modified Pouchitis Disease Activity Index (mPDAI)-defined remissi
56 histology were assessed in 46 patients using Pouchitis Disease Activity Index (PDAI).
57 doscopy with biopsy, with calculation of the pouchitis disease activity index in a prospective cross-
58                                              Pouchitis Disease Activity Index symptom scores were ass
59 phic and disease activity data (based on the Pouchitis Disease Activity Index) and measured levels of
60 ch component score to the total PDAI for the pouchitis group.
61                                Patients with pouchitis had a higher allele 2 carriage rate compared w
62 edolizumab in adult patients in whom chronic pouchitis had developed after undergoing IPAA for ulcera
63                                Patients with pouchitis had significantly higher mean total PDAI score
64 ive colitis, the treatment and prevention of pouchitis has become the one established indication for
65 's disease, ulcerative colitis, obesity, and pouchitis have been correlated with large-scale imbalanc
66 Numerous risk factors for the development of pouchitis have been identified.
67 onic antibiotic therapy to prevent recurrent pouchitis; however, in patients who are intolerant to an
68                The cumulative probability of pouchitis increased from 28% at 5 years to 38% at 10 yea
69                                              Pouchitis is a common long-term complication in patients
70                                              Pouchitis is common after ileal pouch-anal anastomosis (
71                                              Pouchitis is the most common complication after restorat
72                                              Pouchitis is the most common long-term complication of i
73                                              Pouchitis is the most frequent complication of transanal
74                                    Excluding pouchitis, late complications were experienced by 29.1%
75      The efficacy of antibiotic treatment of pouchitis might be attributed to the establishment of an
76 uch phenotype was defined as recurrent-acute pouchitis (n = 6), chronic pouchitis and Crohn's-like di
77                                              Pouchitis often is diagnosed based on symptoms alone.
78 results suggest that FMT/bacteriotherapy for pouchitis patients requires further optimisation.
79    Patients were classified as either having pouchitis (PDAI score > or =7; N = 22) or as not having
80 PDAI score > or =7; N = 22) or as not having pouchitis (PDAI score <7; N = 24).
81     Adult patients with antibiotic-dependent pouchitis received a 2-week course of various antibiotic
82                            Therapy for acute pouchitis remains a short course of antibiotics.
83 s often develop antibiotic-dependent form of pouchitis requiring long-term antibiotic therapy for rem
84          Risk factors for the development of pouchitis should be discussed with patients.
85                                  For chronic pouchitis, studies found success with rifaximin, tinidaz
86                                              Pouchitis that develops in patients with ulcerative coli
87 atients who experience recurrent episodes of pouchitis that respond to antibiotics, the AGA suggests
88         In patients who experience recurrent pouchitis that responds to antibiotics but relapses shor
89 also known as "chronic antibiotic-refractory pouchitis"), the AGA suggests using advanced immunosuppr
90 (also known as "chronic antibiotic-dependent pouchitis"), the AGA suggests using chronic antibiotic t
91 osis and experience intermittent symptoms of pouchitis, the AGA suggests using antibiotics for the tr
92                                              Pouchitis, the most common complication, is inflammation
93 omise for physiologic, nontoxic treatment of pouchitis, ulcerative colitis, and acute infectious diar
94 ecalibacterium were reduced in patients with pouchitis vs controls; there was a negative correlation
95 immune system is distinctly organized during pouchitis, we analyzed tissues from patients with and wi
96 le, and ciprofloxacin as optimal therapy for pouchitis, when preventive therapy with probiotics is no
97 olated ileal disease), perianal fistulae and pouchitis, whereas selected probiotic preparations preve
98 inflammation, particularly Crohn disease and pouchitis, whereas viral, bacterial, fungal, and protozo
99 anagement of postoperative complications and pouchitis will also be discussed.
100         In patients who experience recurrent pouchitis with inadequate response to antibiotics (also